Discussion Forum

Hi All, As a follow up to our DEUSG meeting last week please use this discussion thread for any feedback on an different strength representations being used in the drug model. Presentation is attached to bottom of meeting notes here: https://confluence.ihtsdotools.org/display/USRG/2025-03-13%3A+Virtual https://confluence.ihtsdotools.org/display/USRG/2025-03-13%3A+Virtual    Thanks to Australia for the feedback and presentation. Regards, Shane

Hi All, As a follow up to our DEUSG meeting last week please use this discussion thread for any feedback on an additional 'BoSS Clinical Drug' concept potentially being added to the drug model. Presentation on slide 22 here: https://drive.google.com/file/d/1uuxCV5yL1goTI03tRlPkSXErNJAJN_zK/view https://drive.google.com/file/d/1uuxCV5yL1goTI03tRlPkSXErNJAJN_zK/view  and link to meeting recording here: 2025-02-20: Virtual - User Support Reference Group - SNOMED Confluence https://confluence

Hi All, As a follow up to our DEUSG meeting last week please use this discussion thread for any feedback on additional attributes being added to the MRCM for use in national drug extensions. Presentation here: https://drive.google.com/file/d/1mA4JuuPY7-QEHDOUXjeA7zlvJmnBJybW/view https://drive.google.com/file/d/1mA4JuuPY7-QEHDOUXjeA7zlvJmnBJybW/view and link to meeting recording here: 2025-02-20: Virtual - User Support Reference Group - SNOMED Confluence https://confluence.ihtsdotools.org/

Proposal for change to medicinal products by changing the /1 hour normalization of patch products to usual manufacturer’s stated strength commonly /24 hours (or /1 hour or /16 hours or /72 hours may be appropriate). Do we have consensus in the DEUSG about how this should be represented in the international edition? For example, concentration strength (eg. moving away from normalized /1) or presentation strength - how would this work? - or something else (rate etc)? BN 20241007_ patches str

Please provide comments on the examples below representing the challenges in harmonizing the US Drug Extension with SNOMED CT international release introduced during the 2025-02-20 DEUSG meeting.  Complete details can be found at 2025-02-20: Virtual.  Slides can be found at: https://drive.google.com/file/d/1rkpoLnmKMecO1Bi5xGJVteT2miJy2vZ0/view https://drive.google.com/file/d/1rkpoLnmKMecO1Bi5xGJVteT2miJy2vZ0/view. Recording starts at 55:00.   Summary of 5 examples: Thiothixene: SNOMED has

I hope this is the right place! Clarity around content authored in an extension and then promoted to be included in the International Release. What to do with description IDs, relationship IDs, and language IDs.

We want to use SCT in our new EHR (Millennium) but need to report diagnoses in ICD-10 SE for statistics, reimbursement etc. What different options are there for doing this? Can we do it within M? Should we do it outside M? Is there any software to support this? Please share your experiences of this (good or bad) so we can make a wise choice of way forward. Great thanks in advance!

How can SCT be used within M? We are at the beginning of an implementation of M and are pretty lost when it comes to support for SCT in M. We get different answers depending on who we ask. is there a character limit for terms that will trunctate SCT terms? does M store the concept-ID and/or the descripition-ID or none of those? (the screenshots I have seen have displayed description-ID) Can M handle synonymity; ie different terms are displayed in different parts of the system and are s

Do you puzzle it together by copy/pasting info from previous letters? Or do you have one shared, jointly managed source of truth? If one common source: is it free text, or structured? If structured: do you use Snomed CT concepts? If so: do you search in all relevant hierarchies or in a managed clinical vocabulary? do you manage this in a problem list subset? do you manage your terminology inside our outside your Electronic Medical Record? (I know, it's a lot of questions, but I'm